Cisplatin and Taxane Combinations in Ovarian Cancer
Author Information
Author(s): Engblom P, Rantanen V, Kulmala J, Helenius H, Grènman S
Primary Institution: Turku University Central Hospital
Hypothesis
The study aims to compare the growth-inhibitory effects of cisplatin-paclitaxel and cisplatin-docetaxel combinations in ovarian carcinoma cell lines.
Conclusion
The study found that combining cisplatin with taxanes can lead to a supra-additive or additive effect in ovarian carcinoma cell lines.
Supporting Evidence
- A supra-additive effect was found in four cell lines after using cisplatin with docetaxel.
- Two cell lines showed a supra-additive effect with cisplatin and paclitaxel.
- The degree of supra-additivity increased with higher doses of taxanes.
Takeaway
This study shows that using two cancer drugs together can work better than using them alone in treating ovarian cancer.
Methodology
The study used a 96-well plate clonogenic assay to assess drug interactions in seven human ovarian carcinoma cell lines.
Participant Demographics
Human ovarian carcinoma cell lines were used.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website